EN PL
CASE REPORT
Macrophage activation syndrome in a patient with systemic onset of the juvenile idiopathic arthritis
 
More details
Hide details
 
Submission date: 2016-01-16
 
 
Final revision date: 2016-02-26
 
 
Acceptance date: 2016-02-27
 
 
Online publication date: 2016-03-24
 
 
Publication date: 2016-02-29
 
 
Reumatologia 2016;54(1):42-47
 
KEYWORDS
TOPICS
ABSTRACT
Systemic onset juvenile idiopathic arthritis (sJIA) is defined as arthritis affecting one or more joint usually in the juvenile age group (< 16 years of age) with or preceded by fever of at least 2 weeks duration that is documented to be daily (“quotidian”) for at least 3 days which may be associated with evanescent (non-fixed) erythematous rash or generalized lymph node enlargement or hepatomegaly/splenomegaly/both or serositis. Macrophage activation syndrome (MAS) is a life-threatening complication of sJIA marked by sudden onset of non-remitting high fever, profound depression in all three blood cell lines (i.e. leukopenia, anemia, and thrombocytopenia), hepatosplenomegaly, lymphadenopathy, and elevated serum liver enzyme levels. In children with systemic juvenile idiopathic arthritis, the clinical picture may mimic sepsis or an exacerbation of the underlying disease.
We report a case of a 16-year-old female patient presenting with high grade fever with joint pains and generalized weakness which proved to be systemic onset juvenile idiopathic arthritis with macrophage activation syndrome after ruling out all other differential diagnoses and responded well to intravenous steroids.
 
REFERENCES (14)
1.
Gurion R, Lehman TJ, Moorthy LN. Systemic arthritis in children: A review of clinical presentation and treatment. Int J Inflam 2012; 2012: 271569.
 
2.
Schneider R, Laxer RM. Systemic onset juvenile rheumatoid arthritis. Baillieres Clin Rheumatol 1998; 12: 245-271.
 
3.
Woo P. Systemic juvenile idiopathic arthritis: Diagnosis, management and outcome. Nat Clin Pract Rheumatol 2006; 2: 28-34.
 
4.
Behrens EM, Beukelman T, Gallo L, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: Data from the Pennsylvania systemic onset juvenile arthritis registry (Pasojar). J Rheumatol 2008; 35: 343-348.
 
5.
Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 1985; 106: 561-566.
 
6.
Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001; 85: 421-426.
 
7.
Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-392.
 
8.
Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002; 14: 548-552.
 
9.
Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005; 146: 598-604.
 
10.
Ravelli A, Minoia F, Davì S, et al. 2016 classification criteria for Macrophage Activation Syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis 2016; 75: 481-489.
 
11.
Henter JI. Biology and treatment of familial hemophagocytic lymphohistiocytosis: importance of perforin in lymphocyte-mediated cytotoxicity and triggering of apoptosis. Med Pediatr Oncol 2002; 38: 305-309.
 
12.
Henter JI, Elinder G, Söder O, et al. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 1991; 78: 2918-2922.
 
13.
Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286: 1957-1959.
 
14.
Mouy R, Stephan JL, Pillet P, et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 1996; 129: 750-754.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top